3. 中华医学会糖尿病学分会. 中华糖尿病杂志. 2021; 13(4): 315-409.

4. Adapted from: Piya MK, et al. Br J Clin Pharmacol. 2010; 70(5): 631-644.

5. Palladino R, et al. BMJ Open Diabetes Res Care. 2020; 8(1): e001061.

6. Yadav R, et al. Diabetes Metab Syndr. 2021; 15(5): 102226.

7. Shen X, et al. J Endocrinol Invest. 2023; 46(5): 883-891.

8. Ye J, et al. J Diabetes Investig. 2022; 13(11): 1825-1833.

9. Wang T, et al. Diabetes Care. 2022; 45(8): 1863-1872.

10. Ahlqvist E, et al. Lancet Diabetes Endocrinol. 2018; 6(5): 361-369.

11. Park CY, et al. Br J Ophthalmol. 2012; 96(2): 151-155.

12. Wang X, et al. Ther Clin Risk Manag. 2021; 17: 909-916.

13. van Sloten TT, et al. Lancet Diabetes Endocrinol. 2020; 8(4): 325-336.

14.《二甲双胍临床应用专家共识》更新专家组. 中华内科杂志. 2023; 62(6): 619-630.

15. Jiao Z, et al. J Cell Mol Med. 2021; 25(14): 6733-6745.

16. Natali A, et al. Diabetologia. 2006; 49(3): 434-441.

17. McIntyre HD, et al. Aust N Z J Med. 1991; 21(5): 714-719.

18. Ou HY, et al. Horm Metab Res. 2006; 38(2): 106-111.

19. Garber AJ, et al, Am J Med. 1997; 103(6): 491-497.

20. Hirst JA, et al. Diabetes Care. 2012; 35(2):446-454.

21. Gao Q, et al. Diabetes Res Clin Pract. 2022; 187: 109874.

22. Yuxin H, et al. J Clin Pharm Ther. 2020; 45(3): 470-476.

23. Knowler WC, et al. N Engl J Med. 2002; 346(6): 393-403.

24. Diabetes Prevention Program Research Group. Lancet Diabetes Endocrinol. 2015; 3(11): 866-875.

25. Zhang L, et al. Lancet Diabetes Endocrinol. 2023; 11(8): 567-577.

26. Hirst JA, et al. Diabetes Care. 2012; 35(2): 446-454.

27. UKPDS Group. Lancet. 1998; 352(9131): 854-865.

28. Holman RR, et al., N Engl J Med. 2008; 359(15): 1577-1589.

29. https://easd-elearning.org/44-years-of-the-ukpds/

30. Kooy A, et al. Arch Intern Med. 2009; 169(6): 616-625.

31. 谷伟军, 等. 中华糖尿病杂志. 2015; 7(4): 213-217.

32. Herman M, et al. Prog Cardiovasc Dis. 2017; 60(3): 422-434.

33. Fan YP, et al. J Diabetes Res. 2020; 2020: 9161039.

34. Sun M, et al. Brain. 2024; 147(4): 1474-1482.